Real-world registry for mavacamten and other obstructive HCM treatments
Treatments studied
Part of Heart & circulation clinical trials.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older when you sign consent
- Have a diagnosis of obstructive HCM with certain heart measurements (not explained by other diseases)
- Have preserved heart pumping function (left ventricle ejection fraction at least 55%) from a recent ultrasound/scan
- Have ongoing symptoms even with treatment, such as being limited by activity (NYHA class II to IV in the U.S. study, II to III in Europe)
- Be on typical obstructive HCM medicines (beta blockers, some calcium channel blockers, and/or disopyramide) or currently not tolerating them, OR be starting mavacamten as part of routine care
- Not have certain other heart conditions that can mimic HCM (like amyloidosis or Fabry disease) or other specific valve problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study tests whether adding the drug mavacamten to a heart procedure (radiofrequency ablation) helps people with a thickened heart muscle that blocks blood flow. It may reduce symptoms like chest pain or shortness of breath.
This study tracks how people with obstructive hypertrophic cardiomyopathy feel and function while taking Camzyos (mavacamten). It aims to understand the real-world effects of the medication beyond clinical trials.
This study checks how safe the drug mavacamten is for Korean patients with a type of heart disease called obstructive hypertrophic cardiomyopathy (oHCM). It is for people who are already prescribed the drug by their doctor.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
Hear when a new Obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.